Akanda (AKAN) Competitors $1.26 +0.05 (+4.13%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$1.25 -0.01 (-1.19%) As of 05/23/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKAN vs. CARM, OMGA, IMNN, AIM, LIPO, ATNF, PTIX, KLTO, AEZS, and CHROShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include Carisma Therapeutics (CARM), Omega Therapeutics (OMGA), Imunon (IMNN), AIM ImmunoTech (AIM), Lipella Pharmaceuticals (LIPO), 180 Life Sciences (ATNF), Protagenic Therapeutics (PTIX), Klotho Neurosciences (KLTO), Aeterna Zentaris (AEZS), and Chromocell Therapeutics (CHRO). These companies are all part of the "pharmaceutical products" industry. Akanda vs. Carisma Therapeutics Omega Therapeutics Imunon AIM ImmunoTech Lipella Pharmaceuticals 180 Life Sciences Protagenic Therapeutics Klotho Neurosciences Aeterna Zentaris Chromocell Therapeutics Carisma Therapeutics (NASDAQ:CARM) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations. Do analysts rate CARM or AKAN? Carisma Therapeutics currently has a consensus price target of $1.93, suggesting a potential upside of 940.54%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Akanda.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43Akanda 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, CARM or AKAN? Carisma Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, Akanda has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Is CARM or AKAN more profitable? Akanda has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -314.78%. Akanda's return on equity of 0.00% beat Carisma Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-314.78% -957.20% -96.39% Akanda N/A N/A N/A Do insiders and institutionals believe in CARM or AKAN? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 12.6% of Carisma Therapeutics shares are held by insiders. Comparatively, 20.4% of Akanda shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor CARM or AKAN? Carisma Therapeutics received 18 more outperform votes than Akanda when rated by MarketBeat users. CompanyUnderperformOutperformCarisma TherapeuticsOutperform Votes1878.26% Underperform Votes521.74% AkandaN/AN/A Which has stronger valuation & earnings, CARM or AKAN? Akanda has lower revenue, but higher earnings than Carisma Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.39-$86.88M-$1.56-0.12Akanda$836.66K2.15-$32.28MN/AN/A Does the media favor CARM or AKAN? In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Akanda'saverage media sentiment score. Company Overall Sentiment Carisma Therapeutics Neutral Akanda Neutral SummaryCarisma Therapeutics beats Akanda on 8 of the 14 factors compared between the two stocks. Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.80M$1.22B$5.34B$8.31BDividend YieldN/AN/A5.27%4.11%P/E RatioN/A11.7926.9619.60Price / Sales2.159.32398.81136.05Price / CashN/A10.4038.3234.64Price / Book-0.021.476.774.50Net Income-$32.28M-$56.07M$3.24B$248.60M7 Day Performance4.22%0.23%0.26%-0.89%1 Month Performance6.78%1.22%6.07%7.72%1 Year Performance-84.67%-36.80%18.46%8.62% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkandaN/A$1.26+4.1%N/A-73.6%$1.80M$836,664.000.00110CARMCarisma Therapeutics2.4636 of 5 stars$0.19+14.3%$1.93+912.1%-85.3%$6.95M$19.63M-0.1220Gap UpHigh Trading VolumeOMGAOmega Therapeutics2.2984 of 5 stars$0.13-21.8%$9.20+7,260.0%-94.1%$6.92M$8.10M-0.09120Gap UpIMNNImunon1.5434 of 5 stars$0.47-2.9%$15.50+3,197.2%-20.0%$6.87M$500,000.00-0.2530Trending NewsGap UpAIMAIM ImmunoTech1.5579 of 5 stars$0.09-22.3%$2.75+2,908.8%-77.0%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeLIPOLipella Pharmaceuticals0.714 of 5 stars$2.58+18.3%N/A-44.8%$6.58M$536,357.00-0.614Positive NewsATNF180 Life SciencesN/A$1.15-2.5%N/A-43.2%$6.55MN/A0.007PTIXProtagenic Therapeutics1.1431 of 5 stars$11.10+266.3%N/A-79.6%$6.54MN/A-8.742Analyst UpgradeGap UpHigh Trading VolumeKLTOKlotho NeurosciencesN/A$0.23+2.8%N/AN/A$6.47MN/A-0.64N/AGap DownAEZSAeterna ZentarisN/A$3.60+7.8%N/A-57.0%$6.46M$2.37M-0.2420CHROChromocell TherapeuticsN/A$1.05+5.0%N/A-31.7%$6.45MN/A-0.854Gap Down Related Companies and Tools Related Companies CARM Competitors OMGA Competitors IMNN Competitors AIM Competitors LIPO Competitors ATNF Competitors PTIX Competitors KLTO Competitors AEZS Competitors CHRO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKAN) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredMemorial Day Sale! Save 85% on Weiss Crypto Investor!President Trump just made his first big crypto move … Announcing the creation of a national strategic reser...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKAN Stock Free AKAN Stock Alerts